Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target

Blood

Volumn 118, Issue 16, 2011, Pages 4421-4430

  Zappasodi, Roberta ^a   Bongarzone, Italia ^a   Ghedini, Gaia C ^a   Castagnoli, Lorenzo ^a   Cabras, Antonello D ^a   Messina, Antonella ^a   Tortoreto, Monica ^a   Tripodo, Claudio ^b   Magni, Michele ^a   Carlo Stella, Carmelo ^a,b,c   Gianni, Alessandro M ^a,b,c   Pupa, Serenella M ^a   Di Nicola, Massimo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 105; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOPLASM; DENDRITIC CELL; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MOLECULAR WEIGHT; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; VACCINATION; VACCINATION REACTION;

EID: 80054836022     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-364570     Document Type: Article

References (49)

1. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002;2(12):920-932. (Pubitemid 37323213)
2. Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-262. (Pubitemid 40488631)
3. Multani P, White CA, Grillo-Lopez A. Non-Hodgkin's lymphoma: review of conventional treatments. Curr Pharm Biotechnol. 2001;2(4):279-291. (Pubitemid 33138537)
4. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 1998;10(6):548-551. (Pubitemid 28502249)
5. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359(6):613-626.
6. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
7. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18(17):3135- 3143.
8. Tarella C, Passera R, Magni M, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29(7):814-824.
9. Di Nicola M, Zappasodi R, Carlo-Stella C, et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood. 2009;113(1):18-27.
10. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5(10):761-772. (Pubitemid 41400776)
11. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(2):86-103. (Pubitemid 40942470)
12. Bohonowych JE, Gopal U, Isaacs JS. Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol. 2010;2010:412985.
13. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136(5):823-837.
14. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537-549.
15. Santon A, Garcia-Cosio M, Cristobal E, Pascual A, Muriel A, Garcia-Larana J. Expression of heat shock proteins in classical Hodgkin lymphoma: correlation with apoptotic pathways and prognostic significance. Histopathology. 2011;58(7):1072-1080.
16. Khalil AA, Kabapy NF, Deraz SF, Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta. 2011;1816(2):89-104.
17. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
18. Zappasodi R, Pupa SM, Ghedini GC, et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res. 2010;70:9062-9072.
19. Ros A, Faupel M, Mees H, et al. Protein purification by off-gel electrophoresis. Proteomics. 2002; 2(2):151-156. (Pubitemid 34273084)
20. Caccia D, Micciche F, Cassinelli G, Mondellini P, Casalini P, Bongarzone I. Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line. Mol Cancer. 2010;9:278.
21. Weidle UH, Maisel D, Klostermann S, Schiller C, Weiss EH. Intracellular proteins displayed on the surface of tumor cells as targets for therapeutic intervention with antibody-related agents. Cancer Genomics Proteomics. 2011;8(2):49-63.
22. Cappello F, David S, Peri G, et al. Hsp60: molecular anatomy and role in colorectal cancer diagnosis and treatment. Front Biosci. 2011;3:341-351.
23. Musahl C, Schulte D, Burkhart R, Knippers R. A human homologue of the yeast replication protein Cdc21: interactions with other Mcm proteins. Eur J Biochem. 1995;230(3):1096-1101.
24. Achsel T, Ahrens K, Brahms H, Teigelkamp S, Luhrmann R. The human U5-220kD protein (hPrp8) forms a stable RNA-free complex with several U5-specific proteins, including an RNA unwindase, a homologue of ribosomal elongation factor EF-2, and a novel WD-40 protein. Mol Cell Biol. 1998;18(11):6756-6766. (Pubitemid 28500563)
25. Thompson MW, Tobler A, Fontana A, Hersh LB. Cloning and analysis of the gene for the human puromycin-sensitive aminopeptidase. Biochem Biophys Res Commun. 1999;258(2):234-240. (Pubitemid 29287034)
26. Saito Y, Yamagishi N, Hatayama T. Different localization of Hsp105 family proteins in mammalian cells. Exp Cell Res. 2007;313(17):3707- 3717.
27. Saito Y, Yamagishi N, Hatayama T. Nuclear localization mechanism of Hsp105beta and its possible function in mammalian cells. J Biochem. 2009;145(2):185-191.
28. Nagayama S, Fukukawa C, Katagiri T, et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005;24(41):6201-6212. (Pubitemid 43080043)
29. Klade CS. Proteomics approaches towards antigen discovery and vaccine development. Curr Opin Mol Ther. 2002;4(3):216-223. (Pubitemid 35282866)
30. Hamrita B, Chahed K, Kabbage M, et al. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). Clin Chim Acta. 2008;393(2):95-102.
31. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 1995;269(5230):1585- 1588.
32. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol. 2007;81(1):15-27. (Pubitemid 46021247)
33. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M, Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun. 2001;281(4):936-944. (Pubitemid 32917821)
34. Kai M, Nakatsura T, Egami H, Senju S, Nishimura Y, Ogawa M. Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep. 2003;10(6):1777-1782.
35. Park H-S, Park C-H, Choi B-R, et al. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi. J Cutan Pathol. 2009;36(5):511-516.
36. Hosaka S, Nakatsura T, Tsukamoto H, Hatayama T, Baba H, Nishimura Y. Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Sci. 2006;97(7):623-632. (Pubitemid 44056611)
37. Yamagishi N, Ishihara K, Saito Y, Hatayama T. Hsp105 family proteins suppress staurosporineinduced apoptosis by inhibiting the translocation of Bax to mitochondria in HeLa cells. Exp Cell Res. 2006;312(17):3215-3223. (Pubitemid 44380226)
38. Yamagishi N, Goto K, Nakagawa S, Saito Y, Hatayama T. Hsp105 reduces the protein aggregation and cytotoxicity by expanded-polyglutamine proteins through the induction of Hsp70. Exp Cell Res. 2010;316:2424-2433.
39. Wang X-Y, Chen X, Manjili MH, Repasky E, Henderson R, Subjeck JR. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanomaassociated antigen gp100. Cancer Res. 2003;63(10):2553-2560. (Pubitemid 36605196)
40. Miyazaki M, Nakatsura T, Yokomine K, et al. DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T cells and CD8 T cells. Cancer Sci. 2005;96(10):695-705. (Pubitemid 41723547)
41. Slaby O, Sobkova K, Svoboda M, et al. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol Rep. 2009;21(5):1235-1241.
42. Li Z, Menoret A, Srivastava P. Roles of heatshock proteins in antigen presentation and crosspresentation. Curr Opin Immunol. 2002;14(1):45- 51.
43. Cerchietti LC, Lopes EC, Yang SN, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009;15(12):1369-1376.
44. Yamagishi N. Hsp105 but not Hsp70 family proteins suppress the aggregation of heat-denatured protein in the presence of ADP. FEBS Lett. 2003;555(2):390-396. (Pubitemid 37486062)
45. Yamagishi N, Fujii H, Saito Y, Hatayama T. Hsp105beta upregulates hsp70 gene expression through signal transducer and activator of transcription-3. FEBS J. 2009;276(20):5870-5880.
46. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/ paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic. Cancer Res. 2001;61(13):5137-5144. (Pubitemid 32681546)
47. Vanasse GJ, Winn RK, Rodov S, et al. Bcl-2 overexpression leads to increases in suppressor of cytokine signaling-3 expression in B cells and de novo follicular lymphoma. Mol Cancer Res. 2004; 2(11):620-631. (Pubitemid 39557665)
48. Scuto A, Kujawski M, Kowolik C, et al. STAT3 Inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res. 2011; 71(9):3182-3188.
49. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.